NASDAQ:STTK

Shattuck Labs Stock Forecast, Price & News

$20.01

+0.03 (+0.15 %)

(As of 09/16/2021 02:02 PM ET)

Add

Compare

Today's Range

$19.80

▼

$20.26

50-Day Range

$18.84

▼

$26.68

52-Week Range

$17.51

▼

$60.52

Volume4,996 shs

Average Volume159,597 shs

Market Capitalization$842.88 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive STTK News and Ratings via Email

Sign-up to receive the latest news and ratings for Shattuck Labs and its competitors with MarketBeat's FREE daily newsletter.

About Shattuck Labs

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Shattuck Labs (NASDAQ:STTK) Shares Gap Down to $21.40
September 8, 2021 | americanbankingnews.com

Shattuck Labs, Inc. (NASDAQ:STTK) Receives Average Recommendation of "Buy" from Brokerages
September 2, 2021 | americanbankingnews.com

Shattuck Labs Announces Participation in Upcoming September Conferences
September 1, 2021 | finance.yahoo.com

Shattuck Labs (NASDAQ:STTK) Trading Down 4.3%
August 24, 2021 | americanbankingnews.com

Shattuck Labs (NASDAQ:STTK) Stock Price Up 10.5%
August 23, 2021 | americanbankingnews.com

Piper Jaffray & Co. Buys Dana Inc, Sells South Jersey Industries Inc, Shattuck Labs Inc
August 16, 2021 | finance.yahoo.com

Shattuck Labs Announces Participation in the BTIG Biotechnology Conference
August 6, 2021 | finance.yahoo.com

Shattuck Labs to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 11, 2021
August 4, 2021 | finance.yahoo.com

We're Hopeful That Shattuck Labs (NASDAQ:STTK) Will Use Its Cash Wisely
July 13, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STTK
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.shattucklabs.com
Phone512-900-4690
Employees59
Year FoundedN/A

Sales & Book Value

Annual Sales$9.93 million
Price / Sales84.88
Cash FlowN/A
Price / Cash FlowN/A
Book Value$7.42 per share
Price / Book2.70

Profitability

EPS (Most Recent Fiscal Year)($2.36)
Net Income$-36,600,000.00
Net Margins-453.65%
Return on Equity-28.65%
Return on Assets-20.53%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares42,123,000
Market Cap$842.88 million
Next Earnings Date11/12/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

2.42 out of 5 stars

Medical Sector

156th out of 1,352 stocks

Pharmaceutical Preparations Industry

73rd out of 665 stocks

3.5 Analyst's Opinion

Consensus Rating
Shattuck Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $48.00, Shattuck Labs has a forecasted upside of 139.9% from its current price of $20.01.
Amount of Analyst Coverage
Shattuck Labs has received no research coverage in the past 90 days.

4.7 Community Rank

Outperform Votes
Shattuck Labs has received 7 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Shattuck Labs has received 3 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Shattuck Labs has received 70.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Shattuck Labs and other stocks. Vote “Outperform” if you believe STTK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe STTK will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Shattuck Labs does not currently pay a dividend.
Dividend Growth
Shattuck Labs does not have a long track record of dividend growth.

3.3 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Shattuck Labs insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,426,358.00 in company stock.
Percentage Held by Insiders
18.70% of the stock of Shattuck Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
61.21% of the stock of Shattuck Labs is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Shattuck Labs are expected to grow in the coming year, from ($1.76) to ($1.75) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Shattuck Labs is -7.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Shattuck Labs is -7.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Shattuck Labs has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Shattuck Labs (NASDAQ:STTK) Frequently Asked Questions

Is Shattuck Labs a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Shattuck Labs in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Shattuck Labs stock.
View analyst ratings for Shattuck Labs or view top-rated stocks.

What stocks does MarketBeat like better than Shattuck Labs?

Wall Street analysts have given Shattuck Labs a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Shattuck Labs wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Shattuck Labs' next earnings date?

Shattuck Labs is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for Shattuck Labs.

How were Shattuck Labs' earnings last quarter?

Shattuck Labs, Inc. (NASDAQ:STTK) issued its quarterly earnings data on Wednesday, August, 11th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by $0.21. The firm had revenue of ($4.23) million for the quarter. Shattuck Labs had a negative trailing twelve-month return on equity of 28.65% and a negative net margin of 453.65%.
View Shattuck Labs' earnings history.

What price target have analysts set for STTK?

5 Wall Street analysts have issued 1-year price targets for Shattuck Labs' stock. Their forecasts range from $34.00 to $75.00. On average, they expect Shattuck Labs' share price to reach $48.00 in the next year. This suggests a possible upside of 139.9% from the stock's current price.
View analysts' price targets for Shattuck Labs or view top-rated stocks among Wall Street analysts.

Who are Shattuck Labs' key executives?

Shattuck Labs' management team includes the following people:

Mr. Josiah C. Hornblower, Co-Founder & Chairman (Age 45, Pay $420.43k)
Dr. Taylor H. Schreiber, Co-Founder, CEO & Director (Age 41, Pay $526.11k) (LinkedIn Profile)
Dr. Arundathy Nirmalini Pandite M.B.A., M.D., Chief Medical Officer (Age 62, Pay $583k)
Ms. Casi DeYoung, Chief Bus. Officer (Age 50, Pay $440.66k)
Mr. Andrew R. Neill M.B.A., Chief Financial Officer (Age 35)
Conor Richardson, Sr. Director of Fin. & Investor Relations
Dr. Abhinav A. Shukla Ph.D., Chief Technical Officer
Ms. Erin Ator Thomson J.D., Gen. Counsel (Age 41) (LinkedIn Profile)
Dr. Thomas Lampkin Pharm.D., Head of Regulatory Affairs

Who are some of Shattuck Labs' key competitors?

Some companies that are related to Shattuck Labs include Prothena (PRTA), 23andMe (ME), Zentalis Pharmaceuticals (ZNTL), Verve Therapeutics (VERV), ALX Oncology (ALXO), Insmed (INSM), Emergent BioSolutions (EBS), Cryoport (CYRX), Lyell Immunopharma (LYEL), Nektar Therapeutics (NKTR), Amicus Therapeutics (FOLD), Apellis Pharmaceuticals (APLS), PTC Therapeutics (PTCT), Intra-Cellular Therapies (ITCI) and Cytokinetics (CYTK).
View all of STTK's competitors.

When did Shattuck Labs IPO?

(STTK) raised $150 million in an initial public offering on Friday, October 9th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Evercore ISI acted as the underwriters for the IPO and Needham & Co. was co-manager.

What is Shattuck Labs' stock symbol?

Shattuck Labs trades on the NASDAQ under the ticker symbol "STTK."

Who are Shattuck Labs' major shareholders?

Shattuck Labs' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), BlackRock Inc. (4.16%), Vanguard Group Inc. (2.94%), State Street Corp (2.11%), Clark Estates Inc. NY (1.88%) and Geode Capital Management LLC (0.87%). Company insiders that own Shattuck Labs stock include Andrew R Neill, Erin Ator Thomson, Josiah Hornblower, Redmile Group, Llc and Taylor Schreiber.
View institutional ownership trends for Shattuck Labs.

Which institutional investors are selling Shattuck Labs stock?

STTK stock was sold by a variety of institutional investors in the last quarter, including Clark Estates Inc. NY, Piper Sandler & CO., Goldman Sachs Group Inc., Villere ST Denis J & Co. LLC, Rafferty Asset Management LLC, Bank of America Corp DE, and Citigroup Inc.. Company insiders that have sold Shattuck Labs company stock in the last year include Andrew R Neill, Erin Ator Thomson, Josiah Hornblower, and Taylor Schreiber.
View insider buying and selling activity for Shattuck Labs or view top insider-selling stocks.

Which institutional investors are buying Shattuck Labs stock?

STTK stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Sphera Funds Management LTD., State Street Corp, Geode Capital Management LLC, Pathstone Family Office LLC, Pathstone Family Office LLC, and Northern Trust Corp.
View insider buying and selling activity for Shattuck Labs or or view top insider-buying stocks.

How do I buy shares of Shattuck Labs?

Shares of STTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Shattuck Labs' stock price today?

One share of STTK stock can currently be purchased for approximately $20.01.

How much money does Shattuck Labs make?

Shattuck Labs has a market capitalization of $842.88 million and generates $9.93 million in revenue each year. The company earns $-36,600,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis.

How many employees does Shattuck Labs have?

Shattuck Labs employs 59 workers across the globe.

What is Shattuck Labs' official website?

The official website for Shattuck Labs is www.shattucklabs.com.

How can I contact Shattuck Labs?

The company can be reached via phone at 512-900-4690 or via email at [email protected]

This page was last updated on 9/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here